Dallas, GA
Ketamine Therapy clinics in Dallas
Dallas has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. Texas requires an in person evaluation for Schedule III telehealth prescribing under current DEA rules; most ketamine in Texas is delivered in clinic. Most Dallas clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Dallas only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Dallas, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Dallas sits in the standard range: single IV infusions run 500 to 900 dollars, a full 6 session protocol lands at 3,000 to 5,400, and Spravato copays depend on insurance coverage. A reputable Dallas ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
No clinics found
Reset all filtersRegulatory context
A note on Georgia's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
Georgia Controlled Substances Act (O.C.G.A. 16-13)
Mirrors federal scheduling; no therapeutic access framework for psilocybin or MDMA.
Georgia enforces federal scheduling. The Georgia Composite Medical Board investigates prescriber conduct, including ketamine prescribing and office-based anesthesia. DEA enforcement on ketamine clinics focuses on diversion, compounding sources, and Ryan Haight Act telehealth compliance. Georgia's PDMP requires controlled substance reporting.
Ketamine Therapy in Dallas, answered.
Explore related care